Endovascular Embolization of the Swine Rete Mirabile with Eudragit-E 100 Polymer

BACKGROUND AND PURPOSE: Both adhesive and nonabrasive embolic agents are available for arteriovenous malformation (AVM) embolization. The purpose of this study was to evaluate a novel ethanol-based nonadhesive liquid embolic material in a swine AVM model.

MATERIALS AND METHODS: Eudragit (copolymer of methyl and butyl methacrylate and dimethylaminoethyl methacrylate) was dissolved in 50% ethanol and 50% iopamidol. Eudragit was injected into 9 retia mirabilis (RMs). Ethanol and iopamidol mixture were injected into 4 RMs for comparison. Three RMs emboled with Eudragit mixture were evaluated both angiographically and histopathologically acutely (3–24 hours) and at 30 days and 90 days after embolization.

RESULTS: No procedural complications from Eudragit embolization were noted, including retention or adhesion of the microcatheter. Various degrees of inflammation were observed in the acute and 30-day specimens. Two RMs showed partial recanalization on both histopathology and follow-up angiography in the 30-day group. Arterial fibrosis and calcification were observed in the 30- and 90-day specimens. The internal elastic lamina was disrupted in the 30- and 90-day specimens, but there was no evidence of Eudragit extravasation or hemorrhage. Endothelial damage was seen in all specimens and was particularly severe in the 30- and 90-day specimens.

CONCLUSION: Eudragit polymer induced inflammation in thrombosis similar to n-butyl 2-cyanoacrylate, but without the disadvantages of perivascular hemorrhage and extravasation of embolization material. Although recanalization of some emboled RMs was noted, further investigation into Eudragit as a potentially useful embolic material for brain AVMs is warranted.
radiopaque cast on the nonsubtracted image (white arrow) is located between the ascending pharyngeal artery (black arrow). The right and left retia communicate across the midline. The rete itself is a tiny vascular mesh that structurally resembles the nidus of the human cerebral AVM.

The right and left retia communicate across the midline. The rete itself is a tiny vascular mesh that structurally resembles the nidus of the human cerebral AVM.

Table 1: Summary of swine retia injected with ethanol/iopamidol mixture

| Pig No. | Follow-Up | Histologic Change | Angiographic Change |
|---------|-----------|-------------------|---------------------|
| 1       | 6 hours   | Normal            | —                   |
| 2       | 12 hours  | Normal            | —                   |
| 3       | 24 hours  | Endothelial peel off | —               |
| 4       | 90 days   | Normal            | —                   |

Note: — indicates not present.

Fig 1. Anteroposterior view of the angiograms of swine retia injected with Eudragit mixture (pig 8). Left upper, Control angiogram before embolization shows the rete (arrow). Each rete is located between the ascending pharyngeal artery (arrowhead) and the internal carotid artery (white arrow). Right upper, Immediately after embolization of the rete with Eudragit mixture. Left lower, Angiogram 3 months after the embolization with Eudragit mixture shows complete obliteration of left rete. Right lower, Embolized Eudragit can be seen as radiopaque cast on the nonsubtracted image (white arrowhead).

Fig 2. Anteroposterior view of the angiograms shows recanalization 1 month after embolization with Eudragit mixture (pig 4). Left upper, Before embolization. Right upper, immediately after embolization of the rete with Eudragit mixture. Lower, One month after embolization. The rete shows complete recanalization. Flow around microcatheter was observed. Nine RMs were embolized with Eudragit. Before Eudragit embolization, 50% ethanol was used to fill the space of the microcatheter. Ethanol was injected slowly to avoid migration into the cerebral vasculature. Eudragit embolization was performed with 1.0-ml luer lock syringes by using 0.4 – 0.5 mL of the solution to complete embolization. An injection rate of 0.02 mL/s or slower was used. In some animals, the mixture remaining in the microcatheter was pushed with 50% ethanol (“sandwich” technique). Obliteration of the proximal part of the rete was attempted to minimize a risk of stroke. A mixture of 50% ethanol and 50% iopamidol was injected into 4 retia for comparison purposes (Table 1). For the ethanol/iopamidol mixture, 0.4 mL was injected at the same rate as the Eudragit mixture. Obliteration was confirmed with angiography at the end of each embolization procedure. All animals were followed up at the animal facility, and neurologic assessment was performed regularly.

Angiographic Assessment
Pre- and postembolization angiography was performed to assess vascular obliteration and vasospasm. We also performed follow-up angiography with the animal under general anesthesia just before euthanasia to check for evidence of recanalization within the embolized rete on all swine assessed beyond the acute time points.

Histologic Assessment
All retia were harvested for histologic examination. Tissues were fixed in 10% neutral buffered formalin, processed into paraffin, sectioned at 5 μm, and stained with hematoxylin–eosin (H&E) and elastica–van Gieson. Because Eudragit-E 100 is soluble in ethanol, some of the embolized polymer was dissolved during processing. However, because our purpose was to assess tissue response against this mixture, this technique proved suitable for our study.

Immunohistochemical staining was performed for CD31 by using the Tyramide Signal Intensity Amplification biotin system (Perkin-Elmer, Boston, Mass) to observe the endothelium of affected vessels. All specimens were examined by a veterinary pathologist (C.R.D.).

Results
Embolic and Clinical Observation
Complete closure of the proximal portions of the rete was observed in all Eudragit embolizations. The Eudragit mixture was visualized under fluoroscopy during embolization, and behavior of the material could be monitored for the entire procedure. No
technical problems were experienced with embolizations in this study (Fig 1). Despite very slow injections through 1 microcatheter, no occlusions of the microcatheter were seen. Withdrawal of the microcatheter after embolization was also accomplished without difficulty. There were no clinical complications such as strokes, cardiopulmonary failure, or infection during the follow-up period in the 30-day and 90-day survival groups.

**Angiography**

There was no recanalization of flow within the embolized RMs on angiography immediately after Eudragit embolization. The distal part of the rete, which we did not attempt to embolize, was visualized due to vascular input from small branches of the ipsilateral external carotid artery or from the contralateral rete via the interretial communication. Vasospasm was not detected in the retia injected with ethanol. Recanalization in 2 of 3 embolized retia in animals that survived for 30 days was seen (Fig 2). No embolized retia demonstrated recanalization in the 90-day survival group.

**Histology**

Histologic results for the retia injected with Eudragit mixture are summarized in Table 1, and results for retia injected with ethanol/iopamidol mixture are summarized in Table 1.

Embodied Eudragit mixture appeared as an amorphous eosinophilic intravascular material (Fig 3). Eudragit material was frequently mixed with erythrocytes, attached to the intima of dilated vessels, and accompanied by thrombus. One acute specimen showed severe angionecrosis, but no vessel rupture or extravasation of the Eudragit polymer was observed. Inflammation was seen in vessel walls as well as in the vascular adventitia. In acute specimens, inflammation consisted mainly of neutrophils with fewer mononuclear cells. At 30 days, specimens demonstrated numerous macrophages, lymphocytes, and foreign-body giant cells, with some degree of calcification. At 90 days, fibrosis of affected vessel walls was seen (Fig 4). Some retia demonstrated subendothelial hemorrhage in areas where the endothelium had peeled away from the internal elastic membrane. Elastica-van Gieson staining revealed disruption of the internal elastic membrane in the affected vessel walls. This finding was not observed in specimens harvested earlier than 12 hours after injection.

We observed histologic changes consistent with recanalization in the 2 retia showing antemortem angiographic evidence of recanalization. One rete demonstrated numerous small vessels within the organized part of the embolized artery. We also found a patent lumen lined by endothelium adjacent to encapsulated material within 1 embolized artery (Fig 5).

Immunohistochemical assessment for CD31 revealed endothelial damage ranging from mild peeling away from the internal elastic lamina to complete disappearance of the endothelium. Mural hemorrhages between the detached endothelial layer and the internal elastic membrane were also confirmed with this staining. We did not observe inflammation or disruption of the internal elastic membrane in vessels injected with ethanol/iopamidol mixture and examined immediately and 90 days after injection. Peeling away of the endothelial layer was, however, demonstrated by CD31 staining. The intensity of this change was less than that in the Eudragit-injected arteries.

**Discussion**

**Handling Characteristics**

A nonadhesive liquid embolic agent should demonstrate relative ease of injection and have little or no risk of catheter adhesion when compared with adhesive agents such as n-BCA. In this study, we did not experience any catheter adherence or obstruction of the microcatheter during the injection. Our mixture did require very slow injection to prevent any adverse effect of ethanol on vessels and the inadvertent embolization of cerebral vessels. Slow and controlled injection, however, is easily tolerated due to the cohesive but nonadhesive nature of Eudragit. This slow injection technique is not feasible with adhesive embolic agents.

One important concern for any embolic material is compatibility with endovascular devices. We did not experience problems with damage or dissolution of the microcatheters used for Eudragit embolization in this study.

Several reports describe safety ranges for ethanol injection rates. Sampei et al compared histologic responses to DMSO and 10% and 40% ethanol in rodents. In their study, 10% or 40% ethanol was safer than DMSO when given at a rate of 0.04 mL/s. Yamashita et al injected Eudragit mixture into the renal arteries of dogs at 0.05 mL/s without any complications. Klish et al reported the use of liquid 2-poly-hydroxyethyl-methacrylate for AVM embolization, which requires a high concentration of 80%–90% ethanol as a solvent. They found that this concentrated ethanol solution should be injected at 0.1 mL/s or slower to prevent sclerosis or vasospasm. Hamada et al used 30% ethanol to dissolve EVOH and safely injected it at 0.06 mL/s. We used an injection rate of 0.02 mL/s and did not experience adverse effects in our evaluations. Despite slow injection rates, we did not experience catheter obstruction with Eudragit embolization, which is consistent with a study showing that Eudragit has the lowest viscosity of the liquid embolic agents.

| Pig No. | Follow-Up | Inflammation | Infiltrated Cells | IEM Disruption | Mural Hemorrhage | FBGC | Extravasation of Material | Recanalization |
|---------|-----------|--------------|------------------|----------------|-----------------|------|--------------------------|---------------|
| 1       | 6 hours   | Mild         | NP, MNC          | –              | –               | –    | –                        | –             |
| 2       | 12 hours  | Mild         | NP, MNC          | –              | –               | –    | –                        | –             |
| 3       | 24 hours  | Severe       | NP               | –              | +               | –    | –                        | –             |
| 4       | 30 days   | Mild         | MF, LC, NP, FB   | –              | +               | –    | –                        | –             |
| 5       | 30 days   | Severe       | MF, LC, PC       | –              | +               | –    | –                        | –             |
| 6       | 90 days   | Mild         | MF               | –              | +               | –    | –                        | –             |
| 7       | 90 days   | Moderate     | Fibrosis         | +              | –               | –    | –                        | –             |
| 8       | 90 days   | Moderate     | Fibrosis         | +              | –               | –    | –                        | –             |
| 9       | 90 days   | Moderate     | Fibrosis         | +              | –               | –    | –                        | –             |

Note: IEM indicates internal elastic lamina; FBGC, foreign body giant cell; NP, neutrophil; MNC, mononuclear cell; MF, macrophage; LC, leukocyte; FB, fibroblast; PC, plasma cell; –, not present; +, present.
Radiopacity

Because both Eudragit polymer and ethanol are not inherently radiopaque, 50% iopamidol (370 mg/mL) is added to these mixtures to render them visible under fluoroscopy. This modification allows safe monitoring of the Eudragit mixture injection under road-mapping fluoroscopy. Radiopacity of the cast of the precipitated Eudragit mixture is not permanent; the mixture would lose attenuation as the contrast medium diffuses out of the precipitated cast. Thus, even though the embolized casts were radiopaque at the end of each embolization procedure, this radiopaque cast could not be detected at the follow-up angiography. This loss of visibility is distinct and separate from the issue of recanalization following embolization.

Recanalization Following Embolization

Two retia in this study demonstrated evidence of recanalization. In general, recanalization of the embolized nidus may occur when the embolic material degrades and disperses or when non-embolized vessels are recruited. Fournier et al separated these 2 mechanisms of recanalization, calling the former “revascularization” and the latter “collateralization.” An alternative mechanism of recanalization may occur if there is incomplete embolization due to vasospasm associated with rapid injection of alcohol-based agents. Although vasospasm was a possible factor in these retia that recanalized, we observed no vasospasm in our control animals injected at the same rate with ethanol/iopamidol mixtures. For this reason, we believe that vasospasm was not a likely cause of the observed recanalization. However, we could not identify the mechanism of recanalization with angiography.

We did find histologic evidence of recanalization in the 2 retia that also showed angiographic evidence of recanalization. One finding was similar to that described by Brothers et al, wherein new vessels had developed within the unstable organized embolus. This kind of vascular organization within an embolized artery was only seen in the retia with angiographic evidence of recanalization. Another histologic observation in the retia showing recanalization identified patent lumen lined by endothelium immediately adjacent to, and impinged by, a focus of encapsulated embolized material surrounded by fibrous tissue and variable inflammation (Fig 5). Vinters et al described a similar histologic change in AVMs embolized with bucrylate and speculated that this occurred when the injected material was transferred to the extravascular space and appeared as an encapsulated nodule immediately outside the vessel. They speculated that this process commenced with angionecrosis followed by covering of the embolus with endothelium and proliferation of smooth muscle cells between the embolus and the vessel lumen, which would allow...
Lower loss of normal profiles, calcification, and fibrosis. Macrophages. After embolization. Arteritis and endarteritis consisting of lymphocytes, plasma cells, and neutrophils. This may result from embolic materials. In the experiment by Brothers et al, 13 of 11 animals (27.3%) showed recanalization after embolization with $n$-BCA. A prospective randomized clinical trial of $n$-BCA for human AVM embolization did not assess recanalization; however, there is a retrospective report of recanalization after $n$-BCA embolization. Gruber et al19 reported 13 recanalizations of 26 lesions and concluded that patients who did not receive total or solid casting with $n$-BCA had a risk of recanalization after 3 months of embolization.

On the other hand, Murayama et al10 experienced no angiographic recanalization after experimental embolization of 26 swine retia with an EVOH/DMSO mixture (Onyx). In this preliminary study, we could not show such durability with the Eudragit mixture. However, because their embolization with Onyx was not limited to the proximal part of retina, it should be a less preferable situation for recanalization. The comparative study between those 2 embolic agents with the exact same embolization technique will be addressed in the future study.

Inflammatory Response

We observed variable intensity of inflammation within embolized vessels at both acute and chronic stages. This inflammation was more severe than previously reported for other nonadhesive liquid embolic materials. Because the retina injected with ethanol/iopamidol mixture showed minimal endothelial damage, the inflammation was likely caused by the Eudragit polymer. This is consistent with reports of inflammatory responses to cationic polymers that are also widely used as gene vectors. Some of this inflammation might be caused by interaction between the positively charged polymer and negatively charged blood cells.

An acute inflammatory response with Eudragit was not reported in studies using rat and dog kidneys. Sadato et al11 found acute inflammation in specimens injected with 50% ethanol but not with 10% Eudragit. They speculated that the difference was due to the type of tissue adjacent to the embolized vessel. The vessel injected with ethanol was surrounded by viable tissue, which had the potential to recruit inflammatory cells, whereas the vessels embolized with Eudragit were surrounded by necrotic tissue. Our specimens showed both embolized and intact vessels in close proximity to each other due to the partial embolization, making this theory an attractive explanation for our findings.

Inflammatory cell induction, especially neutrophil by the foreign material, generally starts from 30 minutes to 1 hour after its exposure. Acute inflammation may be pronounced by the period between embolization and sacrifice because our subjects in the acute group survived for at least 6 hours. Jahan et al22 reported a mild acute inflammatory reaction with or without angionecrosis in patients in whom they performed AVM resection a day after Onyx embolization, even though their study of embolization in swine did not show such reaction. The swelling in their acute survival group possibly were sacrificed much earlier than ours. Chronic inflammatory reactions that we observed in this study are similar to those of Onyx in both humans and animals.

Mild-to-severe degrees of inflammation have been reported in both animals and humans by 2 days after $n$-BCA embolization. Angionecrosis and disruption of the internal elastic membrane were observed in these studies. The histologic reaction we observed with the Eudragit mixture is comparable with these reports. In addition, previously reported extravasation of $n$-BCA in retina was not observed with Eudragit in our study, which may make Eudragit a better embolic agent.

Conclusion

We have evaluated a nonadhesive liquid material, Eudragit mixture, for AVM embolization. The handling of this mixture proved relatively easy due to its nonadhesive nature. Although recanalization was observed at 1 month follow-up, no recanalization was seen at 3 months. The overall results of this study
suggest that Eudragit polymer mixture offers promise as a liq-
uid embolic agent for the embolotherapy of AVM.

Acknowledgments
We thank Shigeki Kobayashi, director of Chiba Prefectural
Emergency Center, for donating the Eudragit-E 100. We also thank Pauline Chu, Life Science Research Assis-
tant, Department of Comparative Medicine, Stanford Univer-
sity School of Medicine, for her suggestions and preparation of
specimens. Finally we are grateful to the Röhm America (Pis-
cataway, NJ) for providing the Eudragit-E 100.

References
1. Becker TA, Kipke DR, Presl MG, et al. In vivo assessment of calcium alginate
gel for endovascular embolization of a cerebral arteriovenous malfor-
mation model using the subretinal window. Neurosurgery 2002;51:453–59
2. Hamada J, Kai Y, Morioka M, et al. A nonadhesive liquid embolic agent com-
pounded of ethylene vinyl alcohol copolymer and ethanol mixture for the treat-
ment of cerebral arteriovenous malformations: experimental study. J Neuro-
surg 2002;97:889–95
3. Kirsch J, Yin L, Requejo F, et al. Liquid 2-poly-hydroxyethyl-methacrylate em-
bolization of experimental arteriovenous malformations: feasibility study. AJNR Am J Neuroradiol 2002;23:422–29
4. Taki W, Yonekawa Y, Iwata H, et al. A new liquid material for embolization of
arteriovenous malformations. AJNR Am J Neuroradiol 1990;11:163–68
5. Yamashita K, Taki W, Iwata H, et al. A cationic polymer, Eudragit-E, as a new
liquid embolic material for arteriovenous malformations. Neuroradiology 1996;38(suppl 1):S151–56
6. Kinugasa K, Mandai S, Terai Y, et al. Direct thrombosis of aneurysms with
cellulose acetate polymer. Part II. Preliminary clinical experience. J Neurosurg 1992;77:501–07
7. Mandai S, Kinugasa K, Ohmoto T, Direct thrombosis of aneurysms with cel-
lulose acetate polymer. Part I. Results of thrombosis in experimental aneu-
rysms. J Neurosurg 1992;77:497–500
8. Kazekawa K, Iwata H, Shimozuru T, et al. Nontoxic embolic liquids for treat-
ment of arteriovenous malformations. J Biomed Mater Res 1997;38:79–86
9. Owaki H, Matsuda S, Sakai N, et al. Non-adhesive cyanoacrylate as an em-
bolic material for endovascular neurosurgery. Biomaterials 2000;21:1039–46
10. Murayama Y, Vinsuda F, Ulhoa A, et al. Nonadhesive liquid embolic agent for
cerebral arteriovenous malformations: preliminary histopathological studies in
swine rete mirabile. Neurosurgery 1998;43:1164–75
11. Sadato A, Numaguchi Y, Taki W, et al. Nonadhesive liquid embolic agent: role
of its components in histological changes in embolized arteries. Acad Radiol
1995;2:198–206
12. Shi Z, Huang Z, Zhang Y, et al. Experimental study of Eudragit mixture as a
new nonadhesive liquid embolic material. Chin Med J (Engl) 2002;115:555–58
13. Brothers MF, Kaufmann JC, Fox AI, et al. n-butyl 2-cyanoacrylate-substitute
for IBCA in interventional neuroradiology: histopathologic and polymeriza-
tion time studies. AJNR Am J Neuroradiol 1989;10:777–86
14. Lasjaunias P, Berenstein A. Technical aspects of surgical neuroangiography.
In: Lasjaunias P, Berenstein A, eds. Surgical Neuro-Angiography (2): Endovascu-
lar Treatment of Craniofacial Lesions. Berlin, Germany: Springer-Verlag;
1989:1–56
15. Sampel K, Hashimoto N, Kazekawa K, et al. Histological changes in brain tissue
and vasculature after intracarotid infusion of organic solvents in rats. Neuroradiology 1996;38:291–94
16. Fournier D, Terbrugge K, Rodesch G, et al. Revascularization of brain arterio-
venous malformations after embolization with bucrylate. Neuroradiology 1990;32:497–501
17. Vinters HV, Lundie MJ, Kaufmann JC. Long-term pathological follow-up of
cerebral arteriovenous malformations treated by embolization with bucrylate.
N Engl J Med 1986;314:477–83
18. m-BCA Trial Investigators. m-butyl cyanoacrylate embolization of cerebral ar-
teriovenous malformations: results of a prospective, randomized, multi cen-
ter trial. AJNR Am J Neuroradiol 2002;23:748–55
19. Gruber A, Mazal PR, Bavinszki G, et al. Repermeation of partially embolized
cerebral arteriovenous malformations: a clinical, radiologic, and histologic
study. AJNR Am J Neuroradiol 1996;17:323–31
20. Tan Y, Huang L. Overcoming the inflammatory toxicity of cationic gene vec-
tors. J Drug Target 2002;10:153–60
21. Turunen MP, Hiltunen MO, Ruponen M, et al. Efficient adventitial gene de-
ivery to rabbit carotid artery with cationic polymer-plasmid complexes. Gene
Ther 1999;6:6–11
22. Jahan R, Murayama Y, Gobin YP, et al. Embolization of arteriovenous malfor-
mations with Onyx: clinicopathological experience in 23 patients. Neurosurg
2001;48:984–97